INmune Bio, Inc.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Show More...
-
Website https://www.inmunebio.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 7.38 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.02 -0.07 -1.11 -0.75 -0.74 Dividends USD Payout Ratio % * Shares Mil 11.0 11.0 11.0 10.0 11.0 Book Value Per Share * USD 2.29 2.07 Free Cash Flow Per Share * USD -0.5 Return on Assets % -61.45 -8.82 -69.54 -36.71 -33.17 Financial Leverage (Average) 1.02 1.05 1.04 1.06 Return on Equity % -9.26 -71.82 -38.25 -34.67 Return on Invested Capital % -9.26 -71.82 -38.31 -34.8 Interest Coverage Current Ratio 0.75 6.13 1.03 11.09 6.25 Quick Ratio 0.67 5.48 1.01 10.91 6.01 Debt/Equity 0.010 0.010